Discriminating among degenerative parkinsonisms using advanced 123I-ioflupane SPECT analyses
Abstract 123I-ioflupane single photon emission computed tomography (SPECT) is a sensitive and well established imaging tool in Parkinson’s disease (PD) and atypical parkinsonian syndromes (APS), yet a discrimination between PD and APS has been considered inconsistent at least based on visual inspection or simple region of interest analyses. We here reappraise this issue by applying advanced image analysis techniques to separate PD from the various APS. This study included 392 consecutive patients with degenerative parkinsonism undergoing 123I-ioflupane SPECT at our
This article is available to registered members
Create a free account to access our full library of peer-reviewed research on medical cannabis.
Join — it's freeAlready a member? Log in